Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0B3BS
|
|||
Former ID |
DNC008897
|
|||
Drug Name |
C[Asp22-Lys26][Gly8]GLP-1(7-37)-NH2
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C152H227N41O47
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C4CCCCNC(=O)CC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)C)C)CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC7=CN=CN7)N
|
|||
InChI |
1S/C152H227N41O47/c1-16-77(10)122(149(238)170-80(13)127(216)178-104(59-86-63-162-91-35-24-23-34-89(86)91)138(227)180-100(55-74(4)5)140(229)190-120(75(6)7)147(236)177-93(36-25-27-51-153)130(219)165-67-114(204)171-92(38-29-53-161-152(157)158)129(218)163-65-111(156)201)192-141(230)102(56-83-30-19-17-20-31-83)181-134(223)97(45-49-117(208)209)174-133(222)94-37-26-28-52-160-112(202)61-105(139(228)175-96(43-47-110(155)200)132(221)169-78(11)125(214)168-79(12)126(215)173-94)183-135(224)98(46-50-118(210)211)176-136(225)99(54-73(2)3)179-137(226)101(58-85-39-41-88(199)42-40-85)182-144(233)107(69-194)186-146(235)109(71-196)187-148(237)121(76(8)9)191-143(232)106(62-119(212)213)184-145(234)108(70-195)188-151(240)124(82(15)198)193-142(231)103(57-84-32-21-18-22-33-84)185-150(239)123(81(14)197)189-115(205)68-166-131(220)95(44-48-116(206)207)172-113(203)66-164-128(217)90(154)60-87-64-159-72-167-87/h17-24,30-35,39-42,63-64,72-82,90,92-109,120-124,162,194-199H,16,25-29,36-38,43-62,65-71,153-154H2,1-15H3,(H2,155,200)(H2,156,201)(H,159,167)(H,160,202)(H,163,218)(H,164,217)(H,165,219)(H,166,220)(H,168,214)(H,169,221)(H,170,238)(H,171,204)(H,172,203)(H,173,215)(H,174,222)(H,175,228)(H,176,225)(H,177,236)(H,178,216)(H,179,226)(H,180,227)(H,181,223)(H,182,233)(H,183,224)(H,184,234)(H,185,239)(H,186,235)(H,187,237)(H,188,240)(H,189,205)(H,190,229)(H,191,232)(H,192,230)(H,193,231)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H4,157,158,161)/t77-,78-,79-,80-,81-,82-,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,120-,121-,122-,123-,124-/m0/s1
|
|||
InChIKey |
XYYFVCKJZJFHBW-NINLSKNRSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Inhibitor | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.